Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Entero Therapeutics ( (ENTO) ) just unveiled an update.
Entero Therapeutics, Inc. announced a 1-for-3 reverse stock split of its common stock, approved by the board and shareholders on June 30, 2025, and effective on August 18, 2025. This move aims to increase the per-share bid price above $1.00 to comply with Nasdaq’s listing requirements, thereby maintaining its listing on the Nasdaq Capital Market. The reverse stock split will reduce the company’s outstanding common stock from approximately 4.77 million shares to about 1.59 million shares, and stockholders will receive cash for fractional shares. The company emphasizes the importance of maintaining Nasdaq listing for enhancing shareholder value.
More about Entero Therapeutics
Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company is working on Adrulipase, a recombinant lipase enzyme aimed at aiding digestion in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Average Trading Volume: 6,619,177
Technical Sentiment Signal: Sell
Current Market Cap: $2.92M
See more insights into ENTO stock on TipRanks’ Stock Analysis page.